Marcelo Bigal

Independent Board Member and Chairman of the Science and Technology Committee

2023 - Current

Board Member

2023

Santa Ana Bio leverages deep cell profiling technologies, to design precision biologics in the innate immunity space.

President and CEO

2019

Venture Partner

2019 - 2023

Board Member - Coda Biotherapeutics

2019 - 2022

Chief Medical Officer, SVP

2018 - 2019

Responsible for general medical governance and patient safety oversight relating to all Purdue products, as well as of its subsidiaries, in development and in the market.

Head of Specialty Research and Development & Chief Scientific Officer

2017 - 2018

Leading all specialty research and development, including discovery, early and late stage clinical development, safety and pharmacovigilance, as well setting scientific priorities for the specialty pipeline.

Chief Medical Officer & Head of Global Specialty Clinical Development

2017 - 2017

Head of a group with over 600 employees, in charge of Global Early Stage Clinical Development, Global Late Stage Clinical Development, Global Safety and Pharmacovigilance and Global and Regional Clinical Operations, Biometrics and Data Management. Reports to the President of Global R&D.

Head of Global Specialty Development - Teva Pharmaceuticals

2016 - 2017

Responsible for directing and leading the Clinical Development (Phases 1 to 3),across all specialty areas at Teva. Areas include Migraine/Headaches, Pain, Neurodegeneration, Movement Disorders, Multiple Sclerosis, Respiratory, and others. Responsible for leading the Clinical Pharmacology, Global Clinical Operations and Biometrics groups as well. Reports to the President, Global R&D.

Senior Vice President, Head of Clinical Operations & Innovations and TA Head, Migraine & Headaches

2015 - 2016

Head of R&D group housing Global Clinical Operations, Clinical Pharmacology, Global Biometrics and Global Medical Writing. Therapeutic Area head for the Migraine and Headache programs.

Vice President, Migraine & Headache, Clinical Development R&D at Teva Pharmaceuticals

2014 - 2015

Responsible for all R&D activities required to support the development of medications in migraine and pain, including the development of LBR-101, a monoclonal antibody against CGRP, and of Zecuity, the novel iontophoretic patch for the acute treatment of migraine. Also responsible for providing key strategic input to any further business development activities the company in this field.

Chief Medical Officer

2013 - 2014

Responsible for heading the research development of a humanized monoclonal antibody targeting CGRP, a molecule of relevance in migraine and pain. Direct reports include Head of Preclinical Research, VP of Clinical Operations and VP of Regulatory Affairs.

Head of the Merck Investigator Study Program, Scientific Engagements and Education

2010 - 2013

* Head of an organization that encompassed 13 research committees and is responsible for the review of over 1300 research proposals per year, and for the funding of over 400 studies per year across all therapeutic areas of interest to Merck. The division also reviews company initiated non-regulatory studies globally. Department consists of nearly 40 employees/contractors * Head of scientific education, or the development of unbranded curriculum on drug development for use at academic institutions. * Manager of 5 M.D. Global Executive Directors covering scientific affairs in the areas of HIV, Hepatitis, Anti-Infectious diseases, Ophthalmology, Anesthesiology, and Oncology.

Global Director for Scientific Affairs, Neurology and Psychiatry

2007 - 2010

Responsible for scientific and medical affairs in neurology and psychiatry. Developed the scientific leadership strategy for both areas at Merck (including chairing investigator initiated study programs, running advisory boards)

Director of Research

2006 - 2007

Responsible for the execution of clinical trials (phase 1 to 3), as well as for the development and funding of investigator initiated studies. Over 30 studies conducted during tenure.